Patent · US Active

Combined measurement of anti-CCP and serum amyloid A to assess rheumatoid arthritis

US7981693B2 · kind B2 · utility

0Cited by

0References

5Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Norbert Wild · Geretsried, DE
Veit Peter Grunert · Munich, DE
Johann Karl · Peißenberg, DE
Werner Zolg · Weilheim in Oberbayern, DE

Key dates

Filing date	Aug 24, 2006
Grant date	Jul 19, 2011
Priority date	—
Expiry date	Aug 24, 2026

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present invention relates to a method aiding in the assessment of rheumatoid arthritis. The method especially is used in assessing the absence or presence of rheumatoid arthritis in vitro. It can be best practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of anti-CCP and serum amyloid A and correlating the concentrations determined to the absence or presence of rheumatoid arthritis. To further improve the assessment of RA in a method of this invention the level of one or more additional marker may be determined together with anti-CCP and serum amyloid A and be correlated to the absence or presence of RA. The invention also relates to the use of a marker panel comprising anti-CCP and serum amyloid A in the diagnosis of rheumatoid arthritis and it teaches a kit for performing the method of the invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.